Varisacumab - International Biotech Center Generium

Drug Profile

Varisacumab - International Biotech Center Generium

Alternative Names: Anti-VEGF antibody AT001/r84; Apagin; AT-001 - IBCG; AT001/r84; Bevacizumab biosimilar - International Biotech Center Generium; Fully humanised monoclonal antibody to VEGF; GNR-011; R-84

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas Southwestern Medical Center
  • Developer Affitech Research AS
  • Class Antibodies; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer; Colorectal cancer; Eye-Disorders; Glioblastoma; Non-small cell lung cancer

Most Recent Events

  • 07 Feb 2018 Varisacumab is still in phase II/III trials for Non-small cell lung cancer, Glioblastoma, Colorectal cancer, Breast cancer and Eye disorders in Russia (Generium pipeline, February 2018)
  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
  • 26 Oct 2015 Phase-II/III clinical trials in Breast cancer in Russia (IV) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top